Energy Balance, Exercise, and Cancer Risk

2018 ◽  
Author(s):  
Elaine B Trujillo
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Body Weight Loss ◽  
Normal Weight ◽  
Future Research ◽  
Excess Body Weight ◽  
Healthy Weight

Excess body weight is a risk factor for most cancers. Furthermore, obesity is associated with worsened prognosis after a cancer diagnosis and negatively affects the delivery of systemic therapy, contributes to morbidity of cancer treatment, and may raise the risk of second malignancies and comorbidities. However, an obesity paradox may be occurring in patients with cancer; this paradox has been observed when cancer patients with an elevated body mass index (BMI) have improved survival compared with normal-weight patients, and this has been observed in a variety of cancer patients. The reliance on BMI as a measure of body fatness has limitations in the cancer population; hence, the use of tools that directly measure body fat may be more predictive of cancer risk. Despite public health recommendations for achieving and maintaining a healthy weight for cancer prevention and survivorship, few studies have evaluated the effect of intentional body weight loss on cancer risk, although the evidence is suggestive of a relationship. Future research needs to elucidate if weight loss after a cancer diagnosis decreases the risk of recurrence and mortality, and if so, how much weight loss is needed. This review contains 4 figures, 1 table and 65 references Key words: body weight, cancer, interventions, lifestyle, morbidity, mortality, obesity, prevention, risk, sedentary, survivorship, weight loss

Predictive factors of excess body weight loss 1 year after laparoscopic bariatric surgery

2012 ◽  
Vol 26 (6) ◽  
pp. 1744-1750 ◽  
Author(s):  
Emilio Ortega ◽  
Rosa Morínigo ◽  
Lilliam Flores ◽  
Violeta Moize ◽  
Martin Rios ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Body Weight ◽  
Predictive Factors ◽  
Body Weight Loss ◽  
Excess Body Weight ◽  
Laparoscopic Bariatric Surgery

Tu1603 Prophylactic Effect of Rikkunshito on Body Weight Loss and Malnutrition Accompanied With Anorexia in Esophageal Cancer Patients After Esophagectomy

2014 ◽  
Vol 146 (5) ◽  
pp. S-1086
Author(s):  
Masaki Nakamura ◽  
Mikihito Nakamori ◽  
Toshiyasu Ojima ◽  
Masahiro Katsuda ◽  
Takeshi Iida ◽  
...  
Keyword(s):  
Weight Loss ◽  
Esophageal Cancer ◽  
Body Weight ◽  
Cancer Patients ◽  
Body Weight Loss ◽  
Prophylactic Effect

Adjustable gastric balloons for weight loss – a higher yield of responders compared to non-adjustable gastric balloons

2020 ◽  
Vol 74 (6) ◽  
pp. 513-519
Author(s):  
Adam Vašura ◽  
Evžen Machytka ◽  
Valenti Puig-Divi ◽  
Fernando Saenger ◽  
Ricardo Sorio ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Intragastric Balloon ◽  
Body Weight Loss ◽  
Total Body Weight ◽  
Gastric Ulcers ◽  
Excess Body Weight ◽  
Duration Of Effect ◽  
Extra Weight ◽  
Weight Loss Plateau

Introduction: The degree of efficacy and duration of effect of the intragastric balloon (IGB) can be variable and unpredictable. The Spatz Adjustable Intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease the balloon volume for intolerance and increase the volume for a diminishing effect. The utility/efficacy and responder rate with the Spatz3 AIGB were the subjects of this study. Methods: The results of 227 consecutive patients, without exclusions, in 3 centres implanted with the Spatz3 AIGB were reviewed retrospectively. Mean BMI 35.9; mean weight 99.6 kg; mean Excess Body Weight Loss (EBWL) 30.6%; mean balloon volume 464ml (400–500 ml). Balloon volume adjustments were offered: downward adjustments for intolerance and upward adjustments for weight loss plateau. Results: 227 patients were implanted (mean 10.3 months) yielding a mean weight loss of 15.8 kg; mean 15.7% Total Body Weight Loss (TBWL) and 57.6% Excess Body Weight Loss (EBWL). Response (> 25% EBWL) was achieved in 83.3% of the patients. Downward adjustments in 15 patients (mean 2.3 weeks; mean –120 ml) allowed 12/15 (80%) to continue IGB therapy for a mean of 8.8 months. Upward adjustments in 107 patients (mean of 4.7 months; mean +284ml) yielded an additional mean weight loss of 8.5 kg. The upward-adjusted group at extraction had a mean weight loss of 17.8 kg; 17.2% TBWL and 59.2% EBWL. Two gastric ulcers: one due to NSAIDs and one healed with downward adjustment. Conclusions: In this retrospective review of 227 consecutive Spatz3 AIGB patients, upward adjustments yielded a mean 8.5 kg extra weight loss for those with a weight loss plateau, and downward adjustments alleviated early intolerance in 80% of the patients. These two adjustment functions may be instrumental in yielding a response rate of 83.3%

Remission of Diabetes after Laparoscopic Gastric Bypass

2008 ◽  
Vol 74 (10) ◽  
pp. 948-952 ◽  
Author(s):  
Brian R. Smith ◽  
Marcelo W. Hinojosa ◽  
Kevin M. Reavis ◽  
Ninh T. Nguyen
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Body Weight ◽  
Laparoscopic Gastric Bypass ◽  
Glycosylated Hemoglobin ◽  
Fasting Blood Glucose ◽  
Body Weight Loss ◽  
Excess Body Weight ◽  
Morbidly Obese ◽  
Remission Of Diabetes

Diabetes is a well-recognized and treatable risk factor for cardiac disease, and one of many comorbidities associated with obesity. The aim of this study was to evaluate the clinical outcome of a cohort of morbidly obese patients with documented diabetes who underwent laparoscopic Roux-en-Y gastric bypass. Fifty-nine patients with sufficient follow-up were included in the study. Mean preoperative duration of diabetes was 68 months. At 1 month postoperatively, mean excess body weight loss was 17 per cent with 29 patients (49%) showing improvement and 21 patients (36%) having remission of their disease. Mean excess body weight loss was 67 per cent at 12 months postoperatively with 25 patients (42%) showing improvement and 34 patients (58%) having remission of diabetes. Mean preoperative fasting blood glucose level decreased from 152 g/dL preoperatively to 100 g/dL at 12 months (P = 0.02), whereas glycosylated hemoglobin decreased from 7.9 per cent to 5.7 per cent, respectively (P < 0.01). Patients with remission of diabetes had a shorter length of condition compared with patients with only improvement (43 vs 103 months, P < 0.01). Weight loss associated with laparoscopic gastric bypass significantly improves diabetes control and results in discontinuation or marked reduction of antidiabetic medications in the majority of patients. Improvement in glucose control occurs as early as 1 month postoperatively.

Sign in / Sign up

Export Citation Format

Share Document